Susceptibility of endometrial isolates recovered from women with clinical pelvic inflammatory disease or histologic endometritis to antimicrobial agents

Abstract

The CDC recommended outpatient treatment of pelvic inflammatory disease (PID) is a single dose of ceftriaxone plus 14 days of doxycycline, with or without metronidazole. European guidelines (2017) include moxifloxacin plus ceftriaxone as a first line regimen, particularly for women with Mycoplasma genitalium-associated PID. However, the susceptibility of anaerobic bacteria associated with PID to moxifloxacin is unknown. Our objective was to evaluate the in vitro antibiotic susceptibility of facultative and anaerobic bacteria from the endometrium of women having symptomatic PID and/or histologically confirmed endometritis.